December 16, 2015
AstraZeneca divests Entocort US rights to Perrigo for $380M
AstraZeneca has completed its agreement with Perrigo Company plc for the divestment of US rights to Entocort.
Pharmaceuticals, Biotechnology and Life Sciences
Category: Business
December 16, 2015
Lilly welcomes new board member
Eli Lilly and Company has elected Juan R. Luciano as a new member of its board, effective February 1, 2016.
December 14, 2015
JnJ, Verily in formation of Verb Surgical Inc.
Johnson & Johnson Monday announced the formation of Verb Surgical Inc., an independent surgical solutions company, in collaboration with Verily Life Sciences…
December 14, 2015
Horizon buys Crealta Holdings for $510M
Horizon Pharma plc has entered a definitive agreement to acquire Crealta Holdings LLC for $510 million in cash.
December 10, 2015
Rhizen and Novartis enter deal for PI3K delta gamma inhibitor
Rhizen Pharmaceuticals has entered into an exclusive, worldwide agreement with Novartis for the development and commercialization of Rhizen’s inhaled dual PI3K-delta gamma inhibitor and its closely related compound for various indications.
December 9, 2015
Bristol-Myers wraps up Cardioxyl buy. Dividend increase
Bristol-Myers Squibb Company has completed the previously announced planned acquisition of Cardioxyl Pharmaceuticals, Inc.
December 7, 2015
Johnson Johnson buys Novira Therapeutics
Johnson & Johnson has completed the acquisition of Novira Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company developing innovative therapies for curative treatment of chronic hepatitis B virus (HBV) infection.
December 4, 2015
Genomic Vision partners up with the University-Hospital Institute (IHU) Imagine
Genomic Vision – has signed a strategic partnership with the University-Hospital Institute (IHU) Imagine, the largest European genetic research and care cluster.
December 4, 2015
MaSTherCell will fabricate TxCell’s ASTrIA platform products in Europe
TxCell SA has signed a 5-year agreement with MaSTherCell, a Contract Manufacturing Organization (CMO), based in Belgium.
According to this agreement, MaSTherCell will be the exclusive manufacturer in Europe of all products from TxCell’s ASTrIA platform.
December 4, 2015
India’s Sun Pharmaceutical enters $2.5B US market with its generic version of Gleevec
Sun Pharmaceutical Industries, largest India-based generic pharmaceutical companies, has received approval from the US FDA for its Abbreviated New Drug Application (ANDA) for generic version of Novartis’ Gleevec.